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ARTICLE
Critical role of the HDAC6–cortactin axis in human
megakaryocyte maturation leading to a proplatelet-
formation defect
Kahia Messaoudi1,2,3,4, Ashfaq Ali1,2,3,4, Rameez Ishaq1,2,3,4, Alberta Palazzo1,2,3,4, Dominika Sliwa1,2,3,
Olivier Bluteau1,2,3, Sylvie Souquère5, Delphine Muller1,2,3, Khadija M. Diop6, Philippe Rameau7,
Valérie Lapierre8, Jean-Pierre Marolleau9, Patrick Matthias10, Isabelle Godin1,2,3, Gérard Pierron5,
Steven G. Thomas 11,12, Stephen P. Watson11,12, Nathalie Droin1,2,3,6, William Vainchenker1,2,3, Isabelle Plo1,2,3,
Hana Raslova1,2,3 & Najet Debili1,2,3
Thrombocytopenia is a major side effect of a new class of anticancer agents that target
histone deacetylase (HDAC). Their mechanism is poorly understood. Here, we show
that HDAC6 inhibition and genetic knockdown lead to a strong decrease in human proplatelet
formation (PPF). Unexpectedly, HDAC6 inhibition-induced tubulin hyperacetylation has no
effect on PPF. The PPF decrease induced by HDAC6 inhibition is related to cortactin (CTTN)
hyperacetylation associated with actin disorganization inducing important changes in the
distribution of megakaryocyte (MK) organelles. CTTN silencing in human MKs phenocopies
HDAC6 inactivation and knockdown leads to a strong PPF defect. This is rescued by forced
expression of a deacetylated CTTN mimetic. Unexpectedly, unlike human-derived MKs,
HDAC6 and CTTN are shown to be dispensable for mouse PPF in vitro and platelet pro-
duction in vivo. Our results highlight an unexpected function of HDAC6–CTTN axis as a
positive regulator of human but not mouse MK maturation.
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Megakaryocytes (MKs) are highly specialized bone mar-row cells that give rise to anucleated blood cells knownas platelets1. MK progenitor proliferation occurs by
classical mitosis, which, during MK differentiation, subsequently
switches to an endomitotic mode2–4. At the end of the endomi-
totic process, MK cytoplasm matures, leading to increased
organelle biosynthesis5 and the development of the demarcation
membrane system (DMS)6. Once a MK matures, the DMS
extends to form long pseudopods called proplatelets (PPTs)6 that
fragment, leading to platelet release in marrow sinusoids or lung
circulation.1 Platelet production is due to MK fragmentation by a
dynamic regulation of cytoplasmic extension, which mainly
depends on microtubules (MTs) and actin cytoskeleton. While
MT sliding powers PPT elongation, actin cytoskeleleton dynamics
is critical for early stages of PPF by regulating DMS formation
and actomyosin by controlling cortical contractile forces7–9.
In addition, actin cytoskeleleton is also important for PPT
branching and platelet release ampliﬁcation10,11.
A new class of anticancer agents targeting histone deacetylases
(HDACs) induce profound thrombocytopenia12,13 by several
mechanisms, including a toxic effect on hematopoietic progeni-
tors through reactive oxygen species (ROS) and DNA damage
and an alteration in late MK differentiation leading to a defect in
PPF14. The focus has been on the changes in the MK
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Fig. 1 Cellular expression, localization, and regulation of hHDAC6 during human megakaryopoiesis. a Relative HDAC6 mRNA level expression to HPRT
mRNA at different days of MK maturation evaluated by qRT-PCR. b, c Quantiﬁcation of HDAC6 and acetylated tubulin (Ac-Tubulin) protein levels by
western blotting during MK differentiation from two independent experiments. HSC70 is used as a loading control. d Confocal analysis of HDAC6 (red),
actin (green), and ac-Tubulin (cyan) localization at different stages of megakaryopoiesis (D9 MK in the upper panel and PPT in the lower one). e The
HDAC6 promoter is regulated by RUNX1 and FLI1 in human MKs. Data are presented as fold enrichment by dividing the % ChIP by % IgG. f qRT-PCR
analysis of RUNX1 and HDAC6 mRNA levels after RUNX1 knockdown. Error bars in a, e, and f are SD, error bars in c are SEM
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cytoskeleton, especially on tubulin hyperacetylation and MT
dynamics alteration as the mechanism of HDACi-induced
thrombocytopenia. However, there is no direct evidence that
tubulin hyperacetylation is involved in the defect of MK
maturation15.
In humans, 18 HDACs are grouped into four classes, but the
precise role of these proteins in hemostasis is not well deﬁned.
HDAC6 belongs to the class IIb of HDACs that shuttles between
the cytoplasm and the nucleus16. In contrast to class I HDACs,
the role of HDAC6 has not yet been described during human
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megakaryopoiesis. HDAC6 is well expressed in platelets
and may be involved in platelet functions17,18. Predominantly
cytoplasmic19,20, HDAC6 possesses two catalytically active
domains that deacetylate nonhistone proteins such as tubulin,
HSP90, and cortactin (CTTN)21–23. While HDAC6 over-
expression in diverse cell types results in MT deacetylation, its
inhibition induces MT hyperacetylation, which is thought to
enhance their stability23. Recently, it was shown that hdac6-
deﬁcient mouse platelets, with hyperacetylated marginal bands,
spread faster than their wild-type (WT) counterparts17,18. How-
ever, the precise role of tubulin hyperacetylation has been the
matter of controversy. Indeed, despite tubulin hyperacetylation,
hdac6 knockout mice are viable and develop normally24.
Our present work shows that human HDAC6 is a positive
regulator of MK terminal differentiation and consequently of PPT
generation. Our ﬁndings demonstrate that HDAC6 inhibition
induces a defect in the development of DMS and α-granules and
actin disorganization, thus impairing PPF. This defect is mediated
by CTTN hyperacetylation. We also show that HDAC6 inhibition
in humans and the mouse displays divergent effects on MK dif-
ferentiation due to a differential role of CTTN. Altogether, our
results highlight the role of HDAC6–CTTN axis in human MK
maturation and point to a previously unknown mechanism
underlying the HDACi-induced thrombocytopenia14.
Results
Expression of HDAC6 increases during MK differentiation. In
order to study the function of HDAC6 during megakaryopoiesis,
we determined its expression pattern. CD34+ cells were differ-
entiated to MKs and sorted on expression of CD34 and CD41 at
day 7 of culture. A fraction of the CD41+ cells were grown for 2
and 5 additional days allowing MK maturation. We studied the
expression of HDAC 1–11 transcripts. HDAC3 was the HDAC
expressed at the highest level all along the MK differentiation
and then HDAC2, 1, and 7 (Supplementary Fig. 1). HDAC6
messenger RNA (mRNA) level was also detected and increased
during MK differentiation and was highly expressed at day
12 when MKs were fully mature (Fig. 1a). Similarly, HDAC6
protein was weakly expressed in the CD34+ cells and increased
along MK maturation to peak at day 12 of culture (threefold
increase), as compared to the loading control, HSC70 (Fig. 1b).
Concomitantly, acetylated tubulin (ac-tubulin), a major target of
HDAC6, was highly expressed in CD34+ cells. Tubulin acetyla-
tion decreased (about two-fold) during MK commitment and
remains stable all along differentiation (Fig. 1b, c). By confocal
microscopy, we showed that HDAC6 was predominantly loca-
lized in the cytoplasm of MKs and in PPTs where it colocalized
with the MT and actin cytoskeleton (Fig. 1d).
RUNX1 and FLI1 recruitment at the promoter level of
HDAC6. To analyze the mechanism of HDAC6 upregulation
during megakaryopoiesis, we performed transcription factor-
binding site analysis using TRANSFAC (transcription factor
database) for the human HDAC6 promoter. After analysis, we
identify a potential RUNX1 site at position –247 and design a
qPCR primer set. We next investigated whether RUNX1 might
directly associate with the HDAC6 promoter regulatory element
in human MKs. To address this question, we performed a
chromatin immunoprecipitation (ChIP) study targeting the
HDAC6 promoter area in MKs using antibodies against RUNX1
and FLI1. RUNX1 was highly enriched at the promoter level of
HDAC6 in MKs, whereas a lower enrichment for FLI1 was
observed (Fig. 1e). Our data suggest a direct binding of RUNX1
and FLI1 to HDAC6 promoter close to the transcription start site
(TSS) region. To validate these results, we transduced MKs with a
shC or a shRUNX1 and found that RUNX1 knockdown leads to a
decrease of HDAC6 expression (Fig. 1f).
HDAC6 is the main tubulin deacetylase in megakaryocytes. To
explore the role of HDAC6 during MK differentiation, two
selective HDAC6i, ACY1215 (called ricolinostat) and Tubastatin
A, were used. Both inhibitors are widely used to efﬁciently target
HDAC6 without affecting the deacetylase activity of other
enzymes at low concentrations25,26.
We ﬁrst determined their effects on tubulin and histone H3
acetylation by western blot analysis to assess their efﬁciency and
selectivity, respectively. As shown in Fig. 2a, the two inhibitors
induced a dose-dependent increase of acetylated α-tubulin,
suggesting that HDAC6 might be the main α-tubulin deacetylase
in human MKs. As an HDAC6i can, at high concentrations,
inhibit other HDAC classes, we take advantage of the fact that in
contrast to the other HDACs, HDAC6 does not target H325,27,28.
Thus, we considered that the HDAC6-speciﬁc concentrations
correspond to those that do not alter the level of H3 acetylation.
For Tubastatin A, 1 µM was the maximum dose that remains
speciﬁc for HDAC6 (Fig. 2a). In contrast, ACY1215 begins to
induce H3 acetylation at 5 µM (Fig. 2a, b).
It was previously reported that tubulin can also be deacetylated
by Sirtuin-229. As can be seen in Supplementary Fig. 2a, Sirtuin2
was expressed during MK differentiation. However, its inhibition
did not signiﬁcantly affect tubulin acetylation level (Supplemen-
tary Fig. 2b). Moreover, in the presence of 1 µM ACY1215, a
Sirtuin-2 inhibitor, AGK2 did not further increase tubulin
acetylation (Supplementary Fig. 2 c, d). Altogether, these results
suggest that HDAC6 is the main tubulin deacetylase (TDAC)
during megakaryopoiesis.
HDAC-6 is dispensable for MK progenitors and ploidization.
To study whether HDAC6 inhibition may alter the MK
progenitor compartment, we measured cell growth with
increasing doses of ACY1215 or Tubastatin A (Fig. 2c). At con-
centrations from 50 nM to 1 µM, no effect on the CFU-MK
growth was observed. At higher doses of Tubastatin A and
ACY1215, which affect the other HDACs (Fig. 2a), a decrease in
CFU-MK growth was observed (Fig. 2c).
To explore if HDAC6 may play a role in proliferation, CD34+
cells were seeded in triplicate in serum-free liquid culture in the
presence of TPO and increasing doses of ACY1215 or Tubastatin
A. Both inhibitors added at day 0 of culture at a concentration of
up to 1 µM did not alter the total number of viable cells (Fig. 2d)
or the generation of CD41+CD42+ cells at day 6 of culture
(Fig. 2e). Moreover, at 1 µM or less, both inhibitors did not
Fig. 2 Effects of HDAC6 inhibition on early human megakaryopoiesis. a, b Effect of increasing doses of HDAC6 inhibitors on the level of Ac-Tubulin and
Ac-Histone H3 compared to levels of total Tubulin and Histone H3. a Western blot analysis and b quantiﬁcation. c–e Effect of increasing doses of HDAC6
inhibitors on c compartment of CFU-MK, d cellular proliferation, and e CD41+ CD42+ population. f qRT-PCR analysis of HDAC6, HDAC1, HDAC2, and
HDAC3 mRNA levels after HDAC6 knockdown with both sh1 and sh2. g Western blot analysis of HDAC6 and Ac-Tubulin in sh HDAC6-transduced MKs
and h quantiﬁcation from two independent experiments. i Mean ploidy value of untreated and Tubastatin- or ACY1215-treated MKs. Results are
representative of three independent experiments. Unpaired Student’s t test, *p< 0.05; **p< 0.001; ***p< 0.0001. Error bars in f are SD, all other error bars
are SEM
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impair the CD34+ cell cycle or induce cell death by apoptosis.
Only higher doses (from 2 to 5 µM) inhibited cell viability,
the total CD41+ CD42+ cell production (40% inhibition at 2 and
2.5 µM and 75% for 5 µM of both inhibitors), and the percentage
of cycling CD34+ cells. As these effects on early MK
differentiation are only observed at high doses of inhibitors,
and mimic the effects of pan-HDACi, these results strongly
suggest that this was not related to a selective HDAC6 inhibition.
To conﬁrm these pharmacological results, we generated lentiviral
constructs encoding two different small hairpin RNA (shRNAs)
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against HDAC6 (sh1 and sh2). These constructs, as well as a
vector that contained a control sequence (shC), were transduced
into differentiating MKs at day 5 of culture. Both shRNAs (sh1
and sh2) efﬁciently targeted HDAC6 with a reduction at the
mRNA level of 25% for sh1 and 50% for sh2 without affecting
HDAC 1, 2, and 3 expression levels (Fig. 2f) and led to a 50%
decrease at the level of the protein (Fig. 2g). As expected, HDAC6
knockdown by shRNA increased tubulin acetylation (Fig. 2g, h).
Conﬁrming the previous results obtained with chemical inhibi-
tors, the two shRNA did not affect the cell cycle (Supplementary
Fig. 3a) or cell viability. This conﬁrms that the effects observed at
a low dose of inhibitors are speciﬁc of HDAC6 inhibition.
Therefore, at a high concentration, both inhibitors have HDAC6-
dependent and HDAC6-independent effects, which can be
entangled. The effects of HDAC6i on MK polyploidization were
mild. While ACY1215 at a concentration of 1 µM or less did not
impair MK ploidization, Tubastatin A slightly decreased MK
polyploidization, as illustrated by the mean ploidy (CTL N= 3.4,
ACY1215 N= 3.5, and Tubastatin A N= 2.8) (Fig. 2i).
HDAC6 inhibition leads to MK maturation and PPF defects.
One critical step for platelet production is MK migration toward
the vascular niche along a CXCL12 gradient since PPF and pla-
telet release must occur into the blood circulation. As evidenced
in Supplementary Fig. 3b, both drugs led to a moderate, but
signiﬁcant decrease in the number of MK migrating under
CXCL12 in vitro (nearly a 20% decrease at 1 µM of both
Tubastatin A and ACY1215, n= 3, and p< 0.05 by unpaired
Student’s t test). Furthermore, shRNA HDAC6 inhibition led to a
slight decrease in CXCL12-dependent MK migration (Supple-
mentary Fig. 3c).
To determine if HDAC6 inhibition could alter terminal MK
differentiation, we used PPF as a surrogate marker of this process.
CD41+ cells were sorted on day 8 and further cultured in the
presence or absence of HDAC6i. Both inhibitors gave rise to a
strong dose-dependent decrease in PPF with around 80% and
60% inhibition, for 500 nM of Tubastatin A and for 1 µM of
ACY1215, respectively (Fig. 3a). Higher doses (>1 µM) led to a
complete PPF inhibition associated with the presence of apoptotic
cells as previously reported25. HDAC6i not only altered the rate
of PPF, but also induced the generation of shorter and less-
branched PPTs (Fig. 3b).
Importantly, sh1 and sh2 against HDAC6 strongly decreased
PPF by 40% and 70%, respectively (p< 0.001, p< 0.0001)
(Fig. 3c). Interestingly, after HDAC6 knockdown, MKs remained
alive and round without forming PPTs, as previously observed
with chemical inhibitors.
Ultrastructural studies revealed that HDAC6 knockdown led to
defects of MK maturation characterized by heterogeneity in the
DMS and a defect in α-granule development. While the shC-treated
MKs showed regular distribution of DMSs and α-granules (Fig. 3d i,
ii), the shHDAC6-treated MKs display a paucity in DMSs, the
presence of large multivesicular bodies (MVBs), and heterogeneity
in the α-granules size with enlarged α-granules (Fig. 3d iii, iv). This
result was conﬁrmed by confocal microscopy, showing that
shHDAC6-treated MKs display a heterogeneous distribution of
granules, as assessed by the presence of the von Willebrand factor
(VWF). VWF was colocalized in some granules with the CD63, a
lysosomal marker, suggesting that these double-labeled granules
were MVBs (Fig. 3e). The results were similar with 1 μM ACY1215
(Supplementary Fig. 4).
HDAC6 is dispensable for PPF in mice. Using constitutive
hdac6–/– knockout mice, we next investigated whether Hdac6
affects PPF in the mouse. A complete loss of Hdac6 was asso-
ciated with a concomitant increase in tubulin acetylation level in
BMMKs, which was conﬁrmed by western blot analysis (Fig. 4a, b).
Surprisingly, platelet levels (Fig. 4c), MK number (Fig. 4d), ploidy
level (Fig. 4e), and CFU-MK number (Fig. 4f) were not affected
by hdac6 deletion. To further conﬁrm that Hdac6 does not play a
major role in platelet production, we performed immuno-induced
thrombocytopenia by injecting anti-CD41 into WT and hdac6−/–
mice. No difference was observed in platelet recovery (Fig. 4g).
Moreover, MKs derived from hdac6–/– mice displayed normal
PPF in vitro as compared to WT (Fig. 4h).
To characterize whether the absence of a phenotype in the
mouse is due to a compensation of the BM microenvironnement
or an internal pathway, we investigated the in vitro effects of
Hdac6 inhibition on mouse megakaryopoiesis using ACY1215
and Tubastatin A. Both inhibitors induced tubulin α-hyperace-
tylation in mouse MKs at lower doses (100 and 200 nM,
respectively, Fig. 4i) than that which was previously observed
for human MKs (Fig. 2a). Interestingly, in the mouse, 1 μM of
both inhibitors elicited increased H3 acetylation (Fig. 4i, j). At the
Hdac6-speciﬁc inhibitory concentrations (<1 μM), cell cycle
progression, apoptosis, and endomitosis were not affected as
was PPF (Fig. 4k). Moreover, similar to the pharmacological
inactivation as well as the genetic ablation, hdac6 knockdown
using shRNA had no obvious effect on PPF in vitro (Fig. 4l).
Altogether, these results demonstrate that Hdac6 is dispensable
for PPF in mice not only in vivo but also in vitro in contrast to
humans.
HDAC6 localization in human and murine MKs. To better
understand these differences, we investigated the subcellular
localization of HDAC6 in mouse and human MK. In humans,
HDAC6 is predominantly cytoplasmic (Fig. 1d and the ﬁrst panel
of Fig. 5a), whereas murine Hdac6 (mHdac6) was predominantly
found in the nucleus with only low cytoplasmic levels (Fig. 5a,
middle panel). The speciﬁcity of the antibody was conﬁrmed by
the absence of staining of hdac6–/– MKs (Fig. 5a, lower panel). ac-
tubulin was detected in human and murine MKs. Thus, human
and murine HDAC6 have differing cellular localizations, which
might explain their functional differences.
Cytoplasmic HDAC6 regulates PPF in humans, but not in the
mouse. It was previously shown that the localization of human
(hHDAC6) and mouse Hdac6 (mHdac6) is differently regu-
lated30. While mHdacC6 harbors one functional nuclear export
signal (NES), hHDAC6 has two functional NES (NES1 and
Fig. 4 Hdac6 is dispensable for murine megakaryopoiesis. a, b Western blot analysis and quantiﬁcation of Hdac6 and acetylated tubulin levels. c Platelet
count in WT (n= 20) and hdac6−/− (n= 10) mice. d Similar counts of MK number in the WT and Hdac6 KO bone marrows as attested after vWF staining.
e Hdac6 knockout does not affect MK polyploidization in vivo. f Similar CFU-MK growth in WT and hdac6 KO mice. g Normal recovery of platelet count
in WT and KO mice after thrombocytopenia induction by an anti-CD41 antibody. h Normal PPF from MKs isolated from WT and Hdac6 KO bone marrows.
i, j. Western blot analysis and quantiﬁcation of 48 h-treated MKs with both inhibitors showing a smaller IC50 compared to human MKs and an increase
in histones H3 acetylation at 1 μM. k In vitro proplatelet formation by MKs treated with Tubastatin A or ACY1215. Unpaired Student’s t test, *p< 0.05;
**p< 0.001; ***p< 0.0001. l A shRNA against murine hdac6 (sh-mHDAC6) has no effect on PPF in vitro. Results are representative of three independent
experiments carried on at least three mice for each group (n= 3). Error bars in b, j, k, and l are SEM, error bars in c, d, f–h are SD
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NES2) and a SE14 tetradecapeptide domain, allowing its retention
in the cytoplasm31. To determine the importance of HDAC6
cellular localization, we used two constructs: WT-HDAC6
sequence (WT-HDAC6) and NES1/2 mutant (MUT-HDAC6)
were mutated to prevent recognition by shHDAC6. We show that
while WT-HDAC6 was mainly cytoplasmic, MUT-HDAC6 was
redistributed in MK nuclei, conﬁrming that NES sequences play a
central role in the cytoplasmic retention of human HDAC6
(Fig. 5b). Strikingly, we found that in human MKs, over-
expression of WT-HDAC6, but not of MUT-HDAC6, led to a
signiﬁcant increase in PPT counts, conﬁrming the positive role of
HDAC6 in MK maturation (Fig. 5c). Moreover, PPF rescue
experiments after the introduction of shHDAC6 into MKs show
that expression of WT-HDAC6, but not MUT-HDAC6, rescued
the HDAC6-induced decrease of PPF (Fig. 5c). These results
conﬁrm that the PPF defect after HDAC6 silencing is speciﬁc and
the importance of hHDAC6 cytoplasmic retention is probably to
deacetylate its cytoplasmic targets.
We then sought to determine whether HDAC6 redistribution
in the nucleus of mouse MKs could be at the origin of the absence
of a phenotype in hdac6–/– mice. Cytoplasmic WT-HDAC6 was
overexpressed in murine MKs. Strikingly, in contrast to humans,
WT-HDAC6 expression in mouse MKs did not increase PPT
generation (Fig. 5d).
Taken together, this demonstrates that cytoplasmic localization
is necessary for human PPF by HDAC6, but unexpectedly, the
different localization of human and mouse HDAC6 is not
sufﬁcient to explain its differing role in megakaryopoiesis between
the species.
Tubulin hyperacetylation has no impact on PPF. We next
investigated by which effector(s) HDAC6 modulates MK
maturation and PPF. Considering the available data in the
literature involving the possible role of ac-tubulin in HDACi-
induced thrombocytopenia, we ﬁrst investigated whether
the HDAC6i-induced PPF decrease was due to tubulin hyper-
acetylation. It was suggested that tubulin hyperacetylation may
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increase MT stability and rigidity leading to PPF arrest. To test
this hypothesis, CD41+ cells treated with either Tubastatin A or
ACY1215 were incubated at 37 °C in the presence of 1 µM
nocodazole to allow MT depolymerization. Quite surprisingly,
the kinetics of MT depolymerization in HDAC6i-treated MKs
were comparable to that observed in untreated cells (Fig. 6a),
indicating that HDAC6i-induced tubulin hyperacetylation does
not modify MT stability in MKs.
To assess the role of tubulin hyperacetylation in PPF, we ﬁrst
studied the main tubulin acetyltransferase αTAT expression along
MK differentiation. As for ac-tubulin level, αTAT decreased from
the CD34 to the CD41 stage and remains stable all along MK
differentiation (Supplementary Fig. 5a). In line with our previous
observations, αTAT-knockdown (~50% decrease, Supplementary
Fig. 5b) resulted in a similar PPF compared to cells transduced
with a control vector (Supplementary Fig. 5c), suggesting that the
level of ac-tubulin is not a major regulator of PPF.
Interestingly, the overexpression of a non-ac-tubulin construct
(Tub-40KR) in human MKs failed to rescue the PPF defect
induced by ACY12115 or Tubastatin A (Fig. 6b), suggesting that
tubulin acetylation is not the major effector of HDAC6 in its
effects of PPF.
Cortactin is indispensable for MK maturation and PPF. Given
these results, we centered our investigations on CTTN, another
well-characterized HDAC6 target. We ﬁrst studied CTTN level
during normal MK differentiation and showed that CTTN mark-
edly increased (around 15-fold) from day 7 to day 12 of culture
both at the level of mRNA and protein (Fig. 7a–c). Confocal ima-
ging revealed a cytoplasmic staining of CTTN that colocalized with
the actin cytoskeleton. This was particularly evident at day 12 where
the expression of CTTN was high (Fig. 7d). To determine whether
CTTN is critical for PPF, we generated two efﬁcient shRNAs tar-
geting CTTN (shCTTN-1 and shCTTN-2) that led to 40% and 80%
decrease at mRNA and protein level, respectively (Fig. 7e–g). As for
HDAC6 silencing, neither shRNAs affected the cell cycle (Supple-
mentary Fig. 6a) or MK maturation assessed by the expression of
the CD41 and CD42 (Supplementary Fig. 6b), but lead to a mod-
erate decrease of the mean ploidy (shC N= 4.9, shCTTN N= 3.3,
Supplementary Fig. 6c) and signiﬁcantly decreased MK migration
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(Supplementary Fig. 6d, p< 0.05). Strikingly, CTTN silencing led to
a sharp decrease in PPF compared to cells transduced with a control
shRNA (shC) (Fig. 7h, p< 0.05 and p< 0.01 for shCTTN-1 and
shCTTN-2, respectively).
To conﬁrm these results, a CTTN construct with a silent
mutation to prevent recognition by the shRNA was expressed in
MKs already transduced with shCTTN. Reintroduction of CTTN
completely reversed the PPF defect induced by shCTTN, clearly
demonstrating that the phenotype of the two shRNAs was not
due to off-target effects (Fig. 7i).
HDAC6i inhibits PPF through cortactin hyperacetylation.
Interestingly, as for ac-tubulin, CTTN acetylation decreased
through maturation to increase slightly at day 12 of differentia-
tion (Fig. 7b). Inhibition of HDAC6 by Tubastatin or ACY1215
led to an increase in CTTN acetylation (Fig. 8a, b). Interestingly,
cells treated with Tubastatin A displayed greater hyperacetylation
levels than those observed with ACY1215. Moreover, western blot
analysis showed that selective HDAC6 knockdown with shRNA
also increased CTTN acetylation (Fig. 8c, d). It was previously
reported that both HDAC6 and Sirtuin1 deacetylate CTTN
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in vitro in a cell-type-dependent manner. Although Sirtuin1 was
expressed in MKs (Supplementary Fig. 6e), its inhibition did not
decrease in vitro platelets production (Supplementary Fig. 6f).
To determine whether CTTN is the main effector of HDAC6
during PPF, we overexpressed a non-acetylated CTTN
(CTTN9KR, substitution of the nine acetylated lysines by
arginine) in MKs. It is known that HDAC6 regulates the activity
of CTTN by deacetylating these lysines on the F-actin-binding
domain. Overexpression of CTTN9KR fully rescued the PPF
defect induced by ACY1215, and partially by Tubastatin A
(Fig. 8e). To establish more speciﬁc targeting of HDAC6, we
performed similar experiments with either shHDAC6 and as
expected, CTTN-9KR fully rescued the defect of PPF (Fig. 8f).
It is widely accepted that CTTN deacetylation by HDAC6
increases its afﬁnity for F-actin and enhances its polymerization.
To gain further insights into the role of HDAC6-CTTN
acetylation during PPF, we explored the effects of HDAC6i
on actin dynamics. G (globular) and F (ﬁlamentous) actin of
CD41+ cells were separated by ultracentrifugation, as shown in
Fig. 8g. Tubastatin A and ACY1215 led to a decrease in F-actin
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compared to untreated cells. Consistent with our previous
ﬁndings (Fig. 8e, f), CTTN9KR expression completely rescued
the level of F-actin in cells treated with ACY1215 and partially
in cells treated with Tubastatin A compared to control cells
(Fig. 8g, h). Together, these ﬁndings demonstrate that HDAC6
inhibition decreases actin polymerization that is crucial for both
normal DMS development9 and PPT branching11 through CTTN
hyperacetylation.
HDAC6-cortactin pathway has no effect on murine PPF. To
further understand the basis of HDAC6 differential regulation of
thrombopoiesis in humans and the mouse, we investigated the
role of Cttn during murine PPF. Our results ﬁrst showed that
hdac6 knockout MKs display signiﬁcantly increased Cttn acet-
ylation (Fig. 9a, b). To understand the role of Cttn on murine
megakaryopoiesis, we used the double Cttn/HS1-MK-speciﬁc
knockout mice (DKO); hematopoietic lineage cell-speciﬁc pro-
tein-1 (HS1) being a Cttn homolog. Western blot analysis con-
ﬁrmed the complete loss of both Cttn and HS1 in the knockout
mice (Fig. 9c). DKO mice displayed normal femur MK number
(Fig. 9d), CFU-MK growth (Fig. 9e), mean ploidy (Fig. 9f), and
normal platelet count and volume compared to WT (Fig. 9g) and
similar to single HS1–/– mice32. In vitro, PPF rate was similar in
DKO mice compared to WT (Fig. 9h) with normal cytoplasmic
extensions (Fig. 9i) and platelet recovery after immune depletion
was normal (Fig. 9j).
Discussion
In this study, we show that the HDAC6CTTN axis plays an
important role in humans in contrast to murine megakaryopoi-
esis (Fig. 10). Increasing evidence has revealed the role of HDAC
in the hematopoietic system. Through the deacetylation of his-
tones and a variety of nonhistone proteins, these enzymes reg-
ulate megakaryopoiesis and erythropoiesis. Class I HDACs act as
catalytic subunits of multiprotein corepressors that repress gene
expression by major erythro-MK transcription factors. Indeed,
the HDAC1/2-containing corepressor NuRD regulates GATA1
transcriptional activity33,34 and mice carrying mutations dis-
rupting the NuRD-FOG1/GATA1 interaction display a profound
thrombocytopenia similar to hdac1/2 DKO16. Moreover, we and
others have previously shown that pan-HDACi impairs not only
early human megakaryopoiesis through increased DNA double-
strand breaks and p53-dependent apoptosis, but also late stages of
megakaryopoiesis by another mechanism, which is mainly
mediated by cytoskeleton changes in MKs that are rather due to a
p53-independent mechanism14. It was shown in MK cell lines
that pan-HDACi induces altered expression of Rho-GTPases,
leading to an increase in pMLC235 and also suggested that HDAC
inhibition may impair MK maturation and PPF through tubulin
hyperacetylation and disorganization. Thus, it is possible that the
effects of pan-HDAC inhibition are due to histone hyper-
acetylation for early stages and due to nonhistone hyperacetyla-
tion for late stages of megakaryopoiesis15,35.
HDAC6 plays a central role in the regulation of the MT and
actin cytoskeleton36. Surprisingly, it has been shown that hdac6
knockout mice are viable without hemorrhage24, although the
platelet count has not been reported. To gain further insights
into the role of HDAC6 during human MK differentiation, we
studied its expression and found that, similar to class I HDACs37,
HDAC6 expression is barely detectable in CD34+ cells. HDAC6
expression strongly increases during human megakaryopoiesis.
We then demonstrate that HDAC6 regulates human terminal
MK differentiation without signiﬁcantly affecting early stages of
differentiation.
MK differentiation is regulated by several transcription factors
and interestingly, we found a direct binding of RUNX1 and FLI1
to HDAC6 promoter close to the TSS region. Conﬁrming our
result, RUNX1 knockdown in human MK leads to a decrease of
HDAC6 expression. Our results are in accordance to a reported
HDAC6
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CTTN
CTTN
CTTN
DMS 
formation
PPT 
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Ac
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Fig. 10 Model of HDAC6/cortactin pathway during human proplatelet formation. a CTTN deacetylation by HDAC6 induces ﬁlamentous actin assembly to
support human platelet production. b HDAC6 silencing leads to CTTN hyperacetylation, decreases in its ability to bind F-actin, and inhibits its assembly
impairing MK terminal differentiation
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genome-wide analysis of simultaneous binding sites of RUNX1
and FLI1 transcription factors in primary human MKs38. These
available data also revealed that GATA1, SCL, and at a lesser
extent GATA2 bind to HDAC6 promoter. Altogether, these
results suggest that human HDAC6 may be regulated at a
different extent by these MK transcription factors.
Speciﬁc inhibition of HDAC6 with Tubastatin A, ACY1215,
and two different shRNAs induced a strong decrease in PPF.
Taking into account previous published results, we ﬁrst thought
that HDAC6i-induced MT hyperacetylation was responsible for
the inhibition of PPF. Indeed, HDAC6 inhibition resulted in a
strong increase in ac-tubulin, suggesting that HDAC6 is the main
TDAC in MKs. Furthermore, Sirtuin2, a class III HDAC29 did
not play an important role in MK ac-tubulin because its inhibi-
tion on top of HDAC6 inhibition did not further increase tubulin
acetylation. Strikingly, this induction of tubulin hyperacetylation
did not render the MT cytoskeleton more resistant to nocodazole.
The role of MT acetylation on its dynamics has long been a
matter of controversy. Initially, numerous studies revealed
that HDAC6i-induced tubulin hyperacetylation enhances MTs
stability23,39,40. This was challenged by studies showing that the
highly acetylated MTs of NIH3T3 cells did not induce a resistance
to nocodazole41. These differences may be cell-type dependent.
Moreover, we found that tubulin 40KR, a non-ac-tubulin mimic,
failed to reversed the PPF defect induced by HDAC6i, suggesting
that tubulin acetylation is not involved in the regulation of
PPF. Our results do not support the ﬁndings that implicate
MT hyperacetylation as the mechanism of HDACi-induced
PPF defect15. In this study, it was not shown that the defect in
PPF induced by the pan-HDACi LBH589 was due to tubulin
hyperacetylation in MKs as only a cytoskeleton disorganization
was observed. Surprisingly, our study revealed that HDAC6
knockdown in human MKs led to a disturbed MK maturation,
leading to a heterogeneous defect in DMS development associated
to an unusual large MVB and a defect in granule biogenesis
assessed by the enlarged α-granules. As HDAC6 expression
is regulated by MK-restricted transcription factors, we can
hypothesize that the thrombocytopenia associated to the loss-of-
function mutations in RUNX1, FLI1, and GATA1 in human
pathologies may be partly explained by a decreased expression
of HDAC6, more particularly the abnormalities in DMS and
granule development. We thus oriented our investigations
toward the F-actin-binding protein CTTN, another major
HDAC6 target22,39,42 expressed in mature MKs and its expression
increased in a megakaryoblastic cell line after PMA treatment43.
Herein, we showed that CTTN expression greatly increased
during human megakaryopoiesis and that it colocalized with the
actin cytoskeleton. We showed for the ﬁrst time that CTTN
depletion strongly decreased the percentage of MKs forming
PPTs in vitro. As expected, both HDAC6i and shRNA induced a
dose-dependent increase in CTTN acetylation, leading to a
decrease in the F-actin content and a reduction in its capacity
to bind F-actin, hence impairing actin polymerization and
branching. A CTTN mutant that mimics its deacetylated form
(CTTN-9KR) efﬁciently counteracted HDAC6i-induced actin
depolymerization and PPF decrease.
The main role of HDAC6 on MK terminal differentiation
seems to be related to the organization of actin cytoskeleton and
its role on PPF is controversial. It is well demonstrated that the
driving forces of PPF are mediated by tubulin but not by actin.
However, actin polymerization plays a central role in regulating
DMS formation9 and PPT branching11. Any defect in
DMS organization is associated with a marked defect in PPF. The
link between CTTN and granule development remains to be
investigated. However, recently, it was shown that in humans, a
germline mutation in SRC that has CTTN as the target led to a
thrombocytopenia with a major defect in alpha-granules44.
ARP2/3 complex is involved in DMS organization. It has
been shown that numerous cellular assembly processes require
activation of ARP2/3 by several nucleation-promoting factors
such as CTTN and N-WASP45. We recently demonstrated
that human N-WASP is also critical for PPF46 ; thus, we can
hypothesize that the synergy between HDAC6-CTTN and
N-WASP led to a disturbed MK maturation leading to a
heterogeneous defect in DMS development associated to a defect
in granule biogenesis. Currently, the role of N-WASP in murine
megakaryopoiesis is unknown. Thus, it is possible that in the
mouse, the regulation of the actin cytoskeleton in late MK
differentiation is more dependent on PAK2 and WAVE9,47,48
than on CTNN and N-WASP. However, we cannot exclude that
CTTN may act through other partners such as dynamin 2
whose knockout leads to a defect in DMS formation and PPF49.
However, this hypothesis seems less likely as the results on
dynamin 2 were obtained in the mice where we show that
CTTN is not involved.
The precise mechanism by which mouse MKs compensate
for the lack of Hdac6 and Cttn remains partially unresolved.
A quantitative proteomic study, monitoring the protein level of
other HDAC family members such as Hdac3–7, Hdac9, and
Hdac11 and Sirt2, showed that Hdac6 deﬁciency does not alter
their expression in the mouse liver50. Herein, as others, we also
reported that Hdac6 inactivation in mice does not affect the
acetylation level of histone proteins, showing the absence of a
compensatory increase in the HDAC activity24. Similarly, mice
lacking Cttn and its hematopoietic analog HS1 undergo normal
terminal megakaryopoiesis and are dispensable for MK
podosome formation and platelet function51. One hypothesis
would be that other actin organizers such as WAVE and Arp2/3
complex may be responsible for the lack of a phenotype in the
cttn/HS1 double-knockout mice.
Taken together, this result and others observed in vitro and
in vivo for DIAPH152,53 and WASP54 conﬁrms that the regula-
tion of the cytoskeleton in human and murine MKs is different.
Our in vitro studies have been conﬁrmed in vivo as recently,
the use of ACY1215 (ricolinostat) in human monotherapy or in
combination with other therapy has been shown to lead to
thrombocytopenia55. From our data, it is expected that HDAC6
inhibition will lead to a milder thrombocytopenia than with pan-
HDACi because HDAC6 inhibition will alter only late stages of
megakaryopoiesis. In future clinical trials, it will be important to
determine if the thrombocytopenia is related to the speciﬁc
HDAC6 inhibition or to an off-target effect of the inhibitor on
other HDAC. These ﬁndings open new avenues in the under-
standing of the role of different HDAC and CTTN during human
megakaryopoiesis and may suggest that this axis is implicated in
pathology and in the thrombocytopenia associated with HDACi
in cancer therapy.
Methods
In vitro culture of MKs derived from human CD34+ cells. CD34+ cells were
obtained, in agreement with our institutional ethics committee (Assistance
Publique des Hôpitaux de Paris) and in accordance with the Declaration of
Helsinki, from leukapheresis samples. CD34+ cells were isolated by a positive
selection using immunomagnetic bead cell-sorting system (AutoMacs; Miltenyi
Biotec) and cultured in serum-free medium in the presence of recombinant human
thrombopoietin (rhTPO; 10 ng/mL; Kirin Brewery). Two HDAC6-selective
inhibitors, Tubastatin A (Sigma) and ACY1215, generously provided by Simon
Jones (Acetylon Pharmaceuticals Inc.), were used.
Mice. hdac6–/– mice24 were housed at the Gustave Roussy Animal Facilities
(Villejuif, France) and HS1–/–/CTTNﬂ/ﬂPf4.Cre at the Institute of Cardiovascular
Sciences. All experiments were carried out according to national and institutional
guidelines.
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Immune thrombocytopenia. To induce thrombocytopenia, anti-CD41 was
injected into hdac6 knockout mice, CTTN, and their WT littermates. Platelet count
from both genotypes was determined at 24, 48, and 72 h for hdac6 KO mice and
from 24–168 h for cttn KO mice.
DNA manipulation, shRNA cloning, and lentivirus production. shRNA
constructs targeting the human HDAC6, αTAT, and CTTN (primers) sequences
were cloned, as previously described, in the pRRL-pGK-GFP lentiviral vector
(Open Biosystems).
40KR-Tubulin and 9KR-CTTN were kindly supplied, respectively, by F. Saudou
(Institut Curie, Orsay, France) and Dr. Zhang (Tampa, FL, USA). Human CTTN
plasmid was purchased from Addgene and CTTN silencing was carried out using
the NEB-directed mutagenesis kit. The different constructs were cloned into the
pRRL-EF1α-MCS-PGK-mCherry lentiviral vector. NES-mutant HDAC6 was
generated using the Q5 Site-Directed Mutagenesis Kit according to the
manufacturer’s instructions. Lentiviruses were produced and delivered into
the cells4. pRRL lentiviruses were produced by 293-T cells cotransfected by pCMV-
Gag-Pol and pCMV-VSV-G plasmids (Open Biosystems). Supernatants were
collected at 48, 72, and 96 h after transfection, and were pooled and concentrated
by ultracentrifugation. Virus stocks were kept frozen at –80 °C.
Cell transduction. CD34+ cells were cultured for 5 days in serum-free medium
in the presence of TPO (10 ng/mL) and SCF (50 ng/mL) and transduced with
lentiviral particles for 3 h followed by a second transduction. Cells were sorted
48 h after transduction on the expression of CD41, GFP, and/or Cherry by an
Inﬂux cytometer (Becton Dickinson).
Measurement of ploidy. Hoechst 33342 (10 μg/mL; Sigma) was added at day 10 in
human MK cultures for 1 h 30 min at 37 °C. Cells were then stained with directly
coupled MoAbs: anti-CD41 allophycocyanin (APC) and anti-CD42 phycoerythrin
(1:100; BD Biosciences) for 30 min at 4 °C. The ploidy was measured in the
CD41+/CD42+ cell population by a LSRII ﬂow cytometer equipped with three
lasers (360, 480, and 560 nM excitation). The mean ploidy of MKs was measured4.
The total BM cells from WT mice or hdac6 KO littermate were puriﬁed and
co-stained with FITC-conjugated anti-CD41 antibody and propidium iodide in a
hypotonic citrate solution containing 50 μg/mL RNase. The mean ploidy of MKs
was measured4.
Real-time quantitative RT-PCR. The total RNA was extracted with Trizol (Sigma)
and reverse transcription was performed using 500 ng of total RNA with
SuperScript II Reverse Transcriptase protocol (Life Technologies). Quantitative
PCR was performed using an Applied Biosystems 7500 Real-Time PCR System.
Ampliﬁcation reactions were carried out using Power SyberGreen Master Mix
(Life Technologies) according to the manufacturer’s recommendations. The
expression levels of all studied genes (hdac6, hdac1, hdac2, hdac3, CTTN, αTAT,
sirt1, and sirt2) were calculated relatively to the expression of HPRT and PPIA
as endogenous housekeeping controls. Primer sequences are listed in Supple-
mentary Table 1.
Quantiﬁcation of MK progenitors in semisolid cultures. CD34+ cells were
cultured in serum-free ﬁbrin clot assay with 10 ng/mL of TPO, 50 ng/mL of
SCF (kindly respectively provided by Kirin, Tokyo, Japan and Biovitrum AB,
Stockholm, Sweden) and 10 ng/mL of IL6 (Miletnyi Biotech, France), and in
the presence or absence of various concentrations of Tubastatin A and ACY1215
ranging from 0.05 to 5 µM. After 12–14 days of incubation at 37 °C, MK colonies
were revealed and enumerated14.
A total of 150,000 cells from the total bone morrow of WT and hdac6 KO mice
cells were seeded in triplicate and allowed to form CFU-MK for 5 days. MK
colonies were revealed by acetylcholinesterase staining14.
Effect of HDAC6 on cellular growth and CD41+42+ generation. To assess cel-
lular proliferation, 50,000 CD34+ cells were seeded in the presence of TPO±
Tubastatin A or ACY1215, and viable cells were counted using trypan blue
exclusion at day 6 of differentiation. The quantiﬁcation of the total number of
CD41+ CD42+ cells generated at day 6 of culture in the presence or absence of
increasing doses of HDAC6 inhibitors was derived from the total cell number and
the % of CD41+ CD42+ cells analyzed by ﬂow cytometry.
PPF assay and determination of platelets produced in culture. CD41+-sorted
cells were seeded in triplicate at day 8 of culture in a 96-well plate (3000 cells/well)
in serum-free liquid medium supplemented with 10 ng/mL rhTPO with or without
increasing the concentration of Tubastatin A and ACY1215. MKs displaying PPTs
were counted14,52. Quantiﬁcation of platelets produced in vitro was assessed by
ﬂow cytometry56. Brieﬂy, platelet events were collected without gating using a
log scale for FSC and SSC. An analytical gate was determined based on scatter
properties of normal blood platelets treated similarly. This gate excluded large
contaminating cells (MKs) and a small debris or microparticles. Culture-derived
platelets were enumerated as CD41 events with the same scatter properties as
blood platelets.
Cell cycle analysis. CD34+ cells were grown for 48 h in serum-free liquid medium
with rhTPO (10 ng/mL) in the presence or absence of HDAC6-speciﬁc inhibitors.
Cells were stained for 30 min at 4 °C with propidium iodide (50 µg/mL; Sigma) in a
hypotonic citrate solution containing 50 µg/mL RNase (Sigma). The number of
cells in phase G0, S, and G2/M was analyzed by Canto II ﬂow cytometer.
Assessment of cell viability, apoptosis, and maturation. CD34+ cells were
seeded in triplicate in the presence or absence of increasing doses of Tubastatin A
and ACY1215. Cell viability was measured by trypan blue exclusion, and cell
proliferation was quantiﬁed by manual cell counting. Apoptosis was investigated by
AnnexinV PE and DAPI ﬂow cytometry analysis.
Immunoﬂuorescence and confocal imaging. Immunoﬂuorescence was
performed on CD41+ cells cultured with or without inhibitors4. In brief, cells
were allowed to adhere on poly-L-lysine-coated slides for 1 h at 37 °C, ﬁxed in
4% PFA, permeabilized with 0.2% of Triton, and blocked with 1% BSA before
antibody labeling. Cells were examined under a Leica-SpE confocal microscopy
with ×63/1.4NA oil objective. The following antibodies were used: mouse
anti-ac-tubulin (1:300, Sigma T7451), mouse anti-Tubulin (1:100, Sigma T5293),
rabbit anti-HDAC6 (1:100, Cell Signaling 7558), and rabbit anti-Cortactin
(1:100, Millipore 05-180). FITC-conjugated phalloidin (1:500, Sigma P5282) was
used to stain actin cytoskeleton, mouse anti-CD63 (1:100, Sigma SAB4700215,
clone MEM 259), and rabbit anti-VWF (1:1000, Dako A0082). Appropriate
secondary antibodies conjugated with Alexa 488, Alexa 546, or Alexa 633
(Molecular Probes) were used. DAPI (Molecular Probes) was applied for nucleus
staining. Three-dimensional image analyses were performed with Zeiss Image
Examiner software.
Western blot analysis. CD41+ cells were harvested at different times of culture,
washed once in 1× PBS, and lysed in Nonidet P40 (NP40) buffer containing
protease and phosphatase inhibitors (Roche)14. Lysates were gently sonicated on
ice and protein concentration was assessed using Bradford assay (Bio-Rad). Protein
samples were subjected to SDS–polyacrylamide gel electroporesis. After transfer,
nitrocellulose membranes were blotted with the following 1/1000-diluted
antibodies: anti-HDAC6, anti-acetylated cortactin, and anti-cortactin (from
Millipore, catalog number 07-732, 09-881, and AB3887), anti-ac-tubulin,
anti-tubulin, and anti-actin (Sigma, catalog number T7451, T9026 clone DM1A,
and A2228 clone AC-74), anti-acetylated histone H3 (Cell Signaling, catalog
number 4353), and anti-HSC70 (Abcam, ab19136), followed by revelation by
horseradish peroxidase-linked secondary antibodies and Chemiluminescent HRP
Substrate (Millipore) using IQuant Instrument (GE Healthcare).
G/F actin measurement. CD41+ cells were sorted on day 8 and treated with 1 µM
of either Tubastatin A or ACY1215 for 48 h. Cells were then harvested and washed
twice with ice-cold PBS and resuspended in lysis buffer containing 50 mM PIPES,
50 nM Nacl, 5 nM MgCl2, 5 mM EGTA, 5% glycerol, 0.1% NP40, Triton and
Tween 20, and protease inhibitors and centrifuged for 1 h at 100,000×g at 37°C.
Supernatants containing G-actin were removed and pellets (F-actin) were
resuspended in an equal lysis buffer containing 1 µM cytochalasin D and incubated
for 1 h on ice to stabilize actin ﬁlaments. Equal volumes were loaded and subjected
to western blot analysis.
Migration assessment. CD34+ cells were cultured in serum-free medium in the
presence of rhTPO and SCF with or without HDAC6i. At day 5 of culture, 100,000
cells were allowed to migrate through an 8-µm transwell (Millipore) under SDF-1
(100 ng) for 3 h at 37 °C. Cells were then harvested, stained with speciﬁc antibodies
against CD34, CD41, and CD42, and analyzed by ﬂow cytometry.
Tubulin depolymerization assay. HDAC6i-treated and untreated CD41+ MKs
were plated on collagen-coated slides for 1 h, and then incubated with serum-free
medium containing 1 μM nocodazole (Sigma, France) for the indicated times to
enhance MT depolymerization. Cells were carefully washed, ﬁxed with 4% PFA for
10 min at 37 °C, and permeabilized for 10 min with 0.2% Triton as reported above.
Cells were then stained with an antibody against tubulin (Sigma) and imaged by
Leica confocal microscope.
Chromatin immunoprecipitation. ChIP experiments were performed with
ChIP-IT according to the manufacturer’s instructions (active motif). Brieﬂy, cells
were cross-linked with 37% paraformaldehyde and the reaction was stopped with
glycine, washed twice in cold 1× PBS, lysed in SDS lysis buffer completed with
protease inhibitor cocktail (Millipore), and sonicated using Covaris S220 System.
Antibodies of 5 µg (anti-rabbit IgG, ab171870, Abcam, Paris, France; anti-RUNX1,
ab23980, Abcam, Paris, France; and anti-FLI1, ab15289, Abcam, Strasbourg,
France) were added and incubated overnight. Immunoprecipitated chromatin was
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eluted from the magnetic beads after several washes and the cross-links of these
sequentially immunoprecipitated protein–DNA complexes were then reversed, and
the DNA was analyzed by real-time PCR (Applied Biosystems) for HDAC6 pro-
moter using HDAC6prom-F1: ATGAGGAAACGGAGCACAGAA and HDAC6-
prom-R1: CGGGACTTAACCATGTGACTTTG.
Statistical analyses. Analysis was performed using Prism software (GraphPad
Software Inc) and unpaired t-tests were used for the statistical analyses. Asterisks
indicate signiﬁcant differences: *p-value < 0.05, **p-value < 0.01, and ***p-value<
0.001.
Data availability. Data supporting the ﬁndings of this study are available within
the article and its Supplementary Information ﬁles and from the corresponding
author upon reasonable request.
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